HIV Prevention
Pipeline by Development Stage
Drug Modality Breakdown
Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.
Key Trends
- HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
- Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
- High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity
Career Verdict
Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | BIKTARVY (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate) | Gilead Sciences | $3.2B | 27% | Peak | Stable | 10.5yr |
| 2 | EPCLUSA (velpatasvir and sofosbuvir) | Gilead Sciences | $877M | 7% | Peak | Stable | 8.2yr |
| 3 | TIVICAY (dolutegravir sodium) | GSK | $657M | 6% | Peak | Declining | 4.1yr |
| 4 | TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) | GSK | $632M | 5% | Peak | Declining | 4.1yr |
| 5 | GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) | Gilead Sciences | $626M | 5% | Peak | Stable | 6.9yr |
Drug Class Breakdown
backbone of HIV treatment, stable demand
hepatitis C treatment, mature market
boosting agents in combination regimens
niche mechanism, limited growth
Career Outlook
StableInfectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.
Breaking In
Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.
For Experienced Professionals
Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.
In-Demand Skills
Best For
Hiring Landscape
Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.
Top Hiring Companies
By Department
Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.
Competitive Landscape
16 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 40 trials with date data
Clinical Trials (40)
Total enrollment: 16,770 patients across 40 trials
Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP
Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"
Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men
Pre-Exposure Prophylaxis for Transgender Women in the US and South America
Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)
PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)
ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study
Optimization of a Tenofovir Enema for HIV Prevention
Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel
PrEP & Soccer: A Program for Pharmacy Chains to Increase PrEP Awareness and Access Among Men
Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County
Leveraging Chatbot to Improve PrEP in the Southern United States
California MEPS Hub
Evaluation of a Differentiated Point-of-care Active Case Finding & Management Model to Eliminate Mother-to-Child Transmission of HIV in Malawi
Supporting Oral and Long-acting PrEP Decision Making Among Pregnant Women in Lilongwe, Malawi
WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women
Study for IFE4PrEP Intervention on PrEP Uptake by Southern African American Women
Pilot Mobile Medical Unit Study for I'm Fully Empowered4Her
Express Testing and Same-day Initiation of PrEP Study
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW
Stick2PrEP Cisgender Women and Trans Individuals
Addressing Health Disparities in Engagement, Retention, and Utilization of PrEP Among South Florida Women of Color
Pharmacy Delivery to Expand the Reach of PrEP in Kenya
Long-acting Biomedical HIV Prevention in Transgender Women
Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women
Couple User Preferences in Dual Purpose Prevention Products
Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves
Acceptability and Performance of HIV Self-Testing in a Youth Population in Nigeria
An Accessible Digital Intervention to Promote HIV Testing/Counseling and Prevention Among Adolescents
ATN 151 Work-to-Prevent: Employment as HIV Prevention
Demonstration Project on the Feasibility to Implement PrEP in MSM and TG Women
HOME Study: a Combination Support Package to Increase Uptake of PrEP and HIV/STI Testing
Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)
STI Care Model to Reduce Genital Inflammation and HIV Risk in South African Women
An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial (MTN-003)
Related Jobs in Infectious Diseases
Vice President, Engineering
Vice President, Engineering
Vice President, Engineering
Vice President, Engineering
Director, Anti-infective Pharmacology
Executive Search Recruiting Coordinator
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.